Company news
Erasca, Inc. (NASDAQ:ERAS) news
Erasca, Inc. news releases on 6ix. Latest, Mar 27, 2024: Erasca Announces $45 Million Oversubscribed Private Placement Financing
Press releases — page 2
Erasca Announces $45 Million Oversubscribed Private Placement Financing
March 26, 2024
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 13, 2024
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
December 10, 2023
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
November 27, 2023
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
November 8, 2023
Erasca to Present at Upcoming Investor Conferences in November
November 7, 2023
Erasca to Present at the Cantor Global Healthcare Conference
September 18, 2023
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 4, 2023
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
August 28, 2023
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
August 9, 2023
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
June 21, 2023
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
June 4, 2023
Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
May 30, 2023
Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
May 24, 2023
Erasca Further Strengthens Business Leadership with Two Key Promotions
May 15, 2023
Erasca Reports First Quarter 2023 Financial Results and Business Updates
May 14, 2023
Erasca to Present at the Bank of America Securities 2023 Health Care Conference
May 1, 2023
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
April 30, 2023
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
April 25, 2023
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
April 24, 2023
Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
April 17, 2023
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
April 9, 2023
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
March 22, 2023
Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
March 13, 2023
Erasca to Present at the Guggenheim Oncology Conference 2023
January 31, 2023
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
December 19, 2022
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
December 12, 2022
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
December 8, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 29, 2022
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 8, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 19, 2022
Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
October 11, 2022
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
September 25, 2022
Erasca to Present at the Morgan Stanley Global Healthcare Conference
September 8, 2022
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
September 6, 2022
Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
August 23, 2022
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
August 22, 2022
Erasca Reports Second Quarter 2022 Financial Results and Business Updates
August 10, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
July 17, 2022
Erasca to Present at the 2022 Jefferies Healthcare Conference
June 2, 2022
Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers
June 1, 2022
Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments
May 24, 2022
Erasca Reports First Quarter 2022 Financial Results and Business Updates
May 11, 2022
Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
May 2, 2022
Erasca Appoints Jean Liu to its Board of Directors
April 26, 2022
Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting
April 11, 2022
Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
April 5, 2022